FREMONT, Calif., Sept. 20 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX)
announced today the appointment of John Meyer to vice president, Human
Resources. Mr. Meyer was recently vice president of Human Resources at Somnus
Medical Technologies.
"Abgenix is pleased to have Mr. Meyer, with his extensive experience in
managing rapid growth in both high technology and healthcare companies, join
our team," said R. Scott Greer, chairman and CEO of Abgenix. "Abgenix will
more than double its employee count in 2000 and expects continued growth in
coming years."
Mr. Meyer has more than 20 years experience as a human resources
professional. In addition to Somnus, he has held senior positions at
Vivus, Inc., Target Therapeutics, Chipcom Corporation, PHH Fleet America,
NBI, Inc. and Digital Equipment Corporation. Mr. Meyer received his Bachelor
of Science degree in Business Administration from Colorado State University.
Abgenix is a biopharmaceutical company focused on the development and
commercialization of antibody therapies for a variety of diseases. The
company developed XenoMouse technology to enable the rapid generation of high
affinity, fully human antibody product candidates to essentially any disease
target appropriate for antibody therapy. Abgenix uses its XenoMouse
technology to build a large and diversified product portfolio through the
establishment of licensing arrangements with multiple pharmaceutical,
biotechnology and genomics companies and through the development of its own
internal proprietary products. For more information on Abgenix, visits the
company's website at http://www.abgenix.com.
Statements made in this press release about Abgenix's XenoMouse
technology, product development activities and collaborative arrangements
other than statements of historical fact, are forward looking statements and
are subject to a number of uncertainties that could cause actual results to
differ materially from the statements made, including risks associated with
the success of clinical trials, the progress of research and product
development programs, the regulatory approval process, competitive products,
future capital requirements and the extent and breadth of Abgenix's patent
portfolio. Please see Abgenix's public filings with the Securities and
Exchange Commission for information about risks that may affect Abgenix.
SOURCE Abgenix, Inc.
 back to top
Related links:
http://www.abgenix.com
Company News On-Call:
http://www.prnewswire.com/comp/126548.html or fax,
800-758-5804, ext. 126548
CONTACT:
Ina Cu-Unjieng, Manager, Investor/Public
Relations of Abgenix, Inc., 510-608-4662
|
